ROC-101

AllRock Bio is running a small Phase 2a trial (ROCSTAR, NCT07175038) of ROC-101 in adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1]. ROC-101 is an oral pan-ROCK (Rho-associated kinase) inhibitor - a mechanism class with supportive preclinical biology in pulmonary vascular disease and one approved analog in Japan for a different indication, but no approved ROCK inhibitor for PAH in the US or EU [7]. The 40-patient open-label, single-arm study reads out change in pulmonary vascular resistance (PVR) at 24 weeks, measured by right-heart catheterization, with patients on background standard-of-care therapy [1][7]. Top-line data is realistically a 2027 event. The competitive bar shifted sharply in February 2026 when Gossamer Bio's seralutinib failed Phase 3 PROSERA - clearing one near-term rival but also reaffirming how often Phase 2 PAH signals do not translate [8].

ROC-101 is the lead asset of AllRock Bio, a small private biotech with limited public footprint. The drug is in Phase 2a and the trial is currently recruiting [1]. AllRock Bio's April 2026 announcement of first-patient dosing identifies ROC-101 as a potential first-in-class oral pan-ROCK inhibitor and notes Phase 1 data was presented at ERS Congress [7]. So the mechanism is disclosed (correcting the prior version of this writeup, which leaned on an outdated read of the registry that listed only the compound code). No FDA designations (breakthrough, fast track, orphan, RMAT) appear on public registries. The absence of an orphan drug designation is itself notable - PAH meets prevalence thresholds in the US and EU, the regulatory incentives are meaningful for a single-asset private biotech, and most PAH-focused programs pursue it early. Either the filing is pending and undisclosed, or the company has chosen not to pursue it. Expected timeline: primary endpoint at 24 weeks per patient with a target of 40 (30 PAH + 10 PH-ILD) [7]. Full enrollment at experienced PH centers is plausible in 12-18 months, putting top-line PVR data in 2027-H2. No regulatory submission has been signaled, and shouldn't be - a 40-patient open-label Phase 2a in mixed PAH/PH-ILD doesn't support an NDA. This is signal-finding to justify a registrational program, assuming AllRock Bio raises capital or partners to fund one.

ROC-101 is described by the sponsor as an oral pan-ROCK (Rho-associated coiled-coil-containing protein kinase) inhibitor [7]. ROCK1 and ROCK2 are intracellular kinases that mediate smooth-muscle contraction, endothelial dysfunction, and vascular remodeling. ROCK inhibition causes pulmonary vasodilation and, in preclinical models, attenuates the medial hypertrophy and adventitial fibrosis seen in PAH. The class has clinical precedent: fasudil, an injectable ROCK inhibitor, has been approved in Japan since 1995 for cerebral vasospasm and has been studied (mostly in small, short-duration trials) in PAH with acute hemodynamic effects but no successful registrational program. So the target is biologically validated, but no oral ROCK inhibitor has cleared a Phase 3 PAH trial. ROC-101's positioning as an oral, chronic-use, pan-isoform inhibitor is the differentiator the program needs to demonstrate. In PAH, the pulmonary arteries (the blood vessels carrying blood from the heart to the lungs) progressively narrow and stiffen; the right ventricle fails as it pushes against the rising resistance. Approved drugs work through three pathways: endothelin (ambrisentan, macitentan), nitric oxide / cGMP (sildenafil, tadalafil, riociguat), and prostacyclin (epoprostenol, treprostinil, selexipag). A fourth pathway, activin signaling, was validated in 2024 when Merck's Winrevair (sotatercept) hit the STELLAR Phase 3 endpoint and won FDA approval [2]. PH-ILD is the same plumbing problem on top of fibrotic lung disease. Inhaled treprostinil (Tyvaso) showed benefit in the INCREASE trial and is approved [3]. ROCK inhibition could in principle act as both a vasodilator and an anti-remodeling agent, which is the rationale for pooling PAH and PH-ILD in a single signal-finding study.

ROCSTAR (NCT07175038) is a Phase 2a, multicenter, open-label, single-arm study enrolling 40 adults - up to 30 PAH and up to 10 PH-ILD, WHO functional class II-III [1][7]. The registry record and sponsor disclosure confirm open-label design with no placebo arm; PVR is measured by right-heart catheterization (RHC, an invasive cardiac procedure threading a catheter through the right side of the heart into the pulmonary artery to directly measure pressures and resistance). Primary endpoint is change in PVR from baseline to week 24. PVR is the conventional surrogate endpoint in early PAH trials; Winrevair used it alongside 6-minute walk distance in PULSAR Phase 2 before moving to STELLAR Phase 3 [2]. The FDA accepts PVR as supportive in this setting. A PVR reduction in the 25-35% range from baseline is the rough threshold that has historically signaled a real effect in PAH Phase 2 (Winrevair PULSAR showed ~35% PVR reduction). Anything below ~20% is hard to distinguish from natural-history variation in an open-label cohort. Background therapy: patients receive ROC-101 on top of standard of care, with the eligibility criteria explicitly permitting stable sotatercept as a co-medication [7]. That makes ROC-101 an add-on candidate first; a monotherapy positioning would require a separate program. Analysis plan: the registry records a single pooled primary analysis across both populations, not co-primary or separately powered arms - meaning subgroup signals (PAH alone vs. PH-ILD alone) will be descriptive, not statistical [1]. Design weaknesses: (1) n=40 split 30/10 is underpowered for the PH-ILD subgroup; (2) open-label single-arm with historical/natural-history comparison means any PVR change carries placebo-effect risk - pulmonary vasodilators routinely show open-label PVR drops that don't replicate against placebo. Investors who chase open-label PAH readouts learn this lesson repeatedly. Recruitment status: actively recruiting [1]. No interim readout schedule disclosed. Realistic top-line: 2027-H2.

The model gives this drug a 17% chance of eventually being approved. That number starts from the historical approval rate for Phase 2 drugs in this area - about 27% - and is then adjusted using ten facts about the trial and the company behind it. The estimate is nudged up by a non-randomized trial design and more secondary endpoints than usual, but pulled down by the sponsor's thin approval record and weak earlier-phase results. The remaining facts fall close to average for this stage, so they don't move the number much.

Efficacy risk is the dominant failure mode. Combined PAH + PH-ILD enrollment is risky because the two diseases respond very differently. PAH patients tend to respond well to pulmonary vasodilators. PH-ILD patients often don't and sometimes deteriorate. The riociguat RISE-IIP trial in PH-ILD was halted in 2016 because vasodilation worsened V/Q mismatch - ventilation-perfusion mismatch, where vasodilation sends more blood to lung regions that fibrosis has made unable to oxygenate it, causing arterial oxygen saturation to fall [5]. If ROC-101's vasodilatory action dominates over any anti-remodeling effect, pooling could mask PH-ILD harm with PAH benefit. ROCK inhibition is mechanistically broader than the nitric-oxide pathway riociguat targets, but the V/Q mismatch principle still applies to any pulmonary vasodilator. Safety risk specific to pulmonary vasodilators includes systemic hypotension and the V/Q mismatch problem above. ROCK inhibitors specifically have shown systemic hypotension in PAH trials of fasudil - the cardinal liability for the class. Hepatotoxicity (the black-box concern with endothelin antagonists) is not a known ROCK-inhibitor liability but Phase 1 data is limited to a single ERS Congress presentation [7]. Execution risk: AllRock Bio is a single-asset private biotech. The company's funding history, lead investors, and runway are not publicly visible - material context for whether Phase 3 funding is plausible. Phase 3 in PAH typically requires $150-250M and a CRO with PH-trial experience; the company will likely need to partner or raise on the back of any Phase 2 signal. Commercial risk if approved: PAH is a ~$7-8 billion global market in 2025, growing ~6% annually [9]. Winrevair launched in 2024 to $419M in first-year sales and analyst peak estimates of $2-4 billion [10], rewriting payer expectations. Tyvaso DPI dominates PH-ILD [3]. The Gossamer Bio seralutinib (PDGFR/CSF1R inhibitor) Phase 3 PROSERA failure in February 2026 [8] cleared one near-term oral PAH rival but also reaffirmed how often Phase 2 hemodynamic signals do not survive Phase 3 - a cautionary reference point for any reader weighing ROC-101's Phase 2a readout.

Watch but don't lean in. The mechanism is now disclosed (oral pan-ROCK inhibitor), so the binary 'black-box' framing of the prior version is wrong - but the program is still early, small, and competing in a market where the efficacy bar just got higher. The single data points that would change my view: (1) a Phase 2a PVR reduction ≥25% in the PAH subgroup with no PH-ILD safety signal, and (2) a credible large-pharma partnership before Phase 3 that signals real conviction in the molecule and underwrites the next step. Reasonable check-back schedule: late 2026 for enrollment progress disclosure (ATS, AHA, CHEST abstracts) and any AllRock Bio financing news; 2027-H2 for top-line PVR data. Two things would upgrade this to a real signal: a clean PAH subgroup PVR drop combined with anti-remodeling biomarker data (right-ventricular function, NT-proBNP) that supports a non-vasodilator differentiation story; and Phase 3 funding visibility. Two things would downgrade it to ignore: slow enrollment past 2026-H2 indicating site-level concerns about the mechanism or safety; or a separation of PAH and PH-ILD descriptive analyses showing PVR drops only in PAH on background sotatercept - because then ROC-101 is a third-line add-on vasodilator in a crowded PAH market with a Winrevair-shaped ceiling [10]. Context for non-experts on competing classes: PDGFR (platelet-derived growth factor receptor) is a tyrosine kinase implicated in pulmonary vascular remodeling - the seralutinib target whose Phase 3 just failed [8]. BMP (bone morphogenetic protein) signaling is the pathway sotatercept restores by sequestering activin ligands that suppress BMP. Both are anti-remodeling angles distinct from classical vasodilation. AllRock Bio itself: not on major investor radars. This is a private-market story until Phase 2a produces something to syndicate.